Çok İlaca Dirençli ve Yaygın İlaç Dirençli Tüberküloz Tedavisi
References
WHO consolidated guidelines on tuberculosis. Module 4: treatment and care. Geneva: World Health Organization 2025. Licence: CC BY-NC-SA 3.0 IGO.
Global tuberculosis report 2025. Geneva; World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO.
Tüberküloz Tanı ve Tedavi Rehberi. 3. Baskı Ankara: Neyir Matbaacılık; 2026
Timboe K, Jackson JB, Becker GL. Recent advances in tuberculosis treatment: Towards shorter, safer, and more effective therapies. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 2026; https://doi.org/10.1016/j.jctube.2026.100582
Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet 2022;400:1858–68. https://doi.org/10.1016/S0140-6736(22)02078-5.
Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pumonary tuberculosis. N Engl J Med. 2020; 382: 893-902.
Lange C, Brehm TT, Chesov D, Kherabi. Y, Guglielmetti L. ERS Monograph. Treatment of drug-susceptible and drug-resistant tuberculosis. In: Garcia-Basteiro AL, Öner Eyüpoğlu F, Rangaka MX (eds.) The Challenge of Tuberculosis in the 21st Century.Norwich, UK: Page Bros Group Ltd; 2023.p. 117-138.
Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug resistant tuberculosis. N Engl J Med. 2022; 387: 810-23.
Nyang’wa BT, Berry C, Kazounis E, et al. A 24-Week, All-Oral Regimen for Rifampin- Resistant Tuberculosis. N Engl J Med 2022; 387: 2331-43.
Saukkonen JJ, Duarte R, Munsiff SS, et al.
Updates on the Treatment of Drug-Susceptible and Drug-Resistant
Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2025; 211: pp 15–33.
Guglielmetti L, Khan U, E Velasquez G, et al. Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial. The Lancet Respiratory Medicine 2025; 13: 809-820
Grosu-Creanga IA, Trofor AC, Crişan-Dabija RA, et al. Advers effects induced by second-line antituberculosis drugs: an update based on last WHO treatments recommendations for drug-resistant tuberculosis. Pneumologia 2022; 70: 117-126. doi:10.2478/pneum-2022-0029.70.2021.117-126